Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The classification of colorectal cancer (CRC) by microsatellite instability (MSI) status is important for effective clinical management. In fact, microsatellite instability-high (MSI-H) cancer has distinctive clinicopathological and molecular features. However, microsatellite instability-low (MSI-L) cancer is not clearly defined. The objective of this study was to further clarify the characteristics of MSI-L CRC. A consecutive series of 940 primary CRCs were subdivided into three groups according to the level of MSI and analyzed the clinicopathological features and genetic changes in the KRAS, BRAF and p53 mutation and the loss of heterozygosity (LOH) of adenomatous polyposis coli (APC) gene and methylation status of the O(6)-methylguanine-DNA methyltransferase (MGMT) and MLH1 promoter. Of the 940 CRCs, 5.9% were MSI-H, 7.1% were MSI-L and 87% were microsatellite stable (MSS). KRAS and BRAF mutations were detected in 39.4 and 4.6% of the CRCs, respectively. The frequency of KRAS mutations in MSI-H, MSI-L and MSS cancer was 30, 48 and 39%, respectively. The proportion of KRAS mutations in MSI-L cancer increased from 16 to 63% accompanying the progression from Dukes' A to Dukes' B. While the LOH of D5S346, which is located near the APC gene, and p53 mutation was observed in 75 and 67% of MSI-L CRC at Dukes' A, respectively. These results indicated that the LOH of APC and p53 mutation has already occurred by the Dukes' A lake 'suppressor pathway' but not the KRAS mutation in MSI-L CRCs. The genes involving MSI-L carcinogenesis are similar to MSS but the timing and frequency of the KRAS mutation is different.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general, it is found in approximately 5% of colorectal cancers [102].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [102]
Citations
Cites
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
(2015) · American Journal Of Pathology · doi:10.2353/ajpath · Cited by 4,908
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Microsatellite Instability in Cancer of the Proximal Colon
Thibodeau, S. N., Bren, G., & Schaid, D. (1993) · Science · doi:10.1126/science.8484122 · Cited by 3,130
Ionov, Y., Peinado, M. A., Malkhosyan, S., Shibata, D., & Perucho, M. (1993) · Nature · doi:10.1038/363558a0 · Cited by 2,708
Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer
Leach, F. S., Nicolaides, N. C., Papadopoulos, N., Liu, B., Jen, J., Parsons, R., Peltomäki, P., Sistonen, P., Aaltonen, L. A., Nyström-Lahti, M., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90330-s · Cited by 2,276
Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability
Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., et al. (1995) · Science · doi:10.1126/science.7761852 · Cited by 2,270
Bronner, C. E., Baker, S. M., Morrison, P. T., Warren, G., Smith, L. G., Lescoe, M. K., Kane, M., Earabino, C., Lipford, J., Lindblom, A., et al. (1994) · Nature · doi:10.1038/368258a0 · Cited by 2,052
Genetic instability in colorectal cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/386623a0 · Cited by 1,986
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J.-P. J., Markowitz, S., Willson, J. K. V., Hamilton, S. R., Kinzler, K. W., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6870 · Cited by 1,887
Research works printed but not linked: 14
- Boland, 1998, Cancer Research, 58, 5248
- Risio, 1996, Cancer Research, 56, 5470
- Cunningham, 1998, Cancer Research, 58, 3455
- Halford, 2002, Cancer Research, 62, 53
- Dietmaier, 1997, Cancer Research, 57, 4749
- Parc, 2000, Cancer Research, 60, 2225
- Laiho, 2002, Cancer Research, 62, 1166
- Kambara, 2001, Cancer Research, 61, 7743
- Esteller, 2000, Cancer Research, 60, 2368
- 1996, 111, 307
- Hamelin, 1993, Oncogene, 8, 2213
- 2000, 119, 323
- Esteller, 2001, Cancer Research, 61, 4689
- 1993, 104, 1044
Cited by
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355
Serebriiskii, I. G., Connelly, C., Frampton, G., Newberg, J., Cooke, M., Miller, V., Ali, S., Ross, J. S., Handorf, E., Arora, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11530-0 · Cited by 215
Battaglin, F., Naseem, M., Lenz, H., & Salem, M. E. (2018) · PubMed · Cited by 282
Tong, H., Jiang, Z., Song, L., Tan, K., Yin, X., He, C., Huang, J., Li, X., Jing, X., Yun, H., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.10.019 · Cited by 163
Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers
Kim, C. G., Ahn, J. B., Jung, M., Beom, S. H., Kim, C., Kim, J. H., Heo, S. J., Park, H. S., Kim, J. H., Kim, N. K., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.161 · Cited by 162
“High-frequency microsatellite instability CRCs accounted for only 5.5% of CRCs among Korean patients and for 4.5–5.9% of CRCs among Japanese patients (Asaka et al, 2009; Yamada et al, 2010; Oh et al, 2012).”
BackgroundInfluentialTomita, N., Ishida, H., Tanakaya, K., Yamaguchi, T., Kumamoto, K., Tanaka, T., Hinoi, T., Miyakura, Y., Hasegawa, H., Takayama, T., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01881-4 · Cited by 175
Self-citationImmunotherapy in Colorectal Cancer: Current and Future Strategies
Ooki, A., Shinozaki, E., & Yamaguchi, K. (2021) · Journal of the Anus Rectum and Colon · doi:10.23922/jarc.2020-064 · Cited by 118
Self-citationPrognostic value ofKRASandBRAFmutations in curatively resected colorectal cancer
Kadowaki, S., Kakuta, M., Takahashi, S., Takahashi, A., Arai, Y., Nishimura, Y., Yatsuoka, T., Ooki, A., Yamaguchi, K., Matsuo, K., et al. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i4.1275 · Cited by 98
Yamanaka, T., Oki, E., Yamazaki, K., Yamaguchi, K., Muro, K., Uetake, H., Sato, T., Nishina, T., Ikeda, M., Kato, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.0414 · Cited by 76
Self-citationMGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers
Shima, K., Morikawa, T., Baba, Y., Nosho, K., Suzuki, M., Yamauchi, M., Hayashi, M., Giovannucci, E. L., Fuchs, C. S., & Ogino, S. (2010) · Cancer Causes & Control · doi:10.1007/s10552-010-9698-z · Cited by 75
“The O(6)-methylguanine-DNA methyltransferase (MGMT) gene encodes DNA repair protein and is frequently inactivated in colorectal cancer [1, 2].”
BackgroundFujiyoshi, K., Yamamoto, G., Takahashi, A., Arai, Y., Yamada, M., Kakuta, M., Yamaguchi, K., Akagi, Y., Nishimura, Y., Sakamoto, H., et al. (2017) · Oncology Reports · doi:10.3892/or.2016.5323 · Cited by 74
Self-citationSclafani, F., Gullo, G., Sheahan, K. D., & Crown, J. P. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.11.003 · Cited by 76
Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer
Inamori, K., Togashi, Y., Fukuoka, S., Akagi, K., Ogasawara, K., Irie, T., Motooka, D., Kobayashi, Y., Sugiyama, D., Kojima, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.137365 · Cited by 57
“Approximately 10%–20% of CRCs are diagnosed as MSI-H/dMMR, with some ethnic variances, such as approximately 5% of Japanese CRC patients (34).”
Self-citationYomoda, T., Sudo, T., Kawahara, A., Shigaki, T., Shimomura, S., Tajiri, K., Nagasu, S., Fujita, F., Kinugasa, T., & Akagi, Y. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-07110-z · Cited by 51
Microsatellite instability testing in Korean patients with colorectal cancer
Oh, J. R., Kim, D., Lee, H. S., Lee, H. E., Lee, S. M., Jang, J., Kang, S., Ku, J., Jeong, S., & Park, J. (2012) · Familial Cancer · doi:10.1007/s10689-012-9536-4 · Cited by 47
“Japanese patients with colorectal cancer [41, 42].”
Ishida, H., Yamaguchi, T., Tanakaya, K., Akagi, K., Inoue, Y., Kumamoto, K., Shimodaira, H., Sekine, S., Tanaka, T., Chino, A., et al. (2018) · Journal of the Anus Rectum and Colon · doi:10.23922/jarc.2017-028 · Cited by 47
Self-citationAmitay, E. L., Carr, P. R., Jansen, L., Walter, V., Roth, W., Herpel, E., Kloor, M., Bläker, H., Chang-Claude, J. C., Brenner, H., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy170 · Cited by 41
Barresi, V., Bonetti, L. R., & Bettelli, S. R. (2015) · Pathology · doi:10.1097/pat.0000000000000300 · Cited by 41
“Indeed the incidence of KRAS mutations was shown to increase during the progression of CRC from stage I to stage II.(26) In accordance, we observed a significant correlation between KRAS mutations and pT stage of CRC and the rationale for this is that oncogenic KRAS mutations enhance the invasive potential of CRC cell…”
BackgroundClinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations
Ogura, T., Kakuta, M., Yatsuoka, T., Nishimura, Y., Sakamoto, H., Yamaguchi, K., Tanabe, M., Tanaka, Y., & Akagi, K. (2014) · Oncology Reports · doi:10.3892/or.2014.3165 · Cited by 41
Self-citationCurrent clinical topics of Lynch syndrome
Tanakaya, K. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1282-7 · Cited by 38
Fujiyoshi, K., Yamaguchi, T., Kakuta, M., Takahashi, A., Arai, Y., Yamada, M., Yamamoto, G., Ohde, S., Takao, M., Horiguchi, S., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1088 · Cited by 35
“KRAS mutations in exons 2, 3, and 4 were analyzed by highresolution melting analysis, using a RotorGene Q (Qiagen, Hilden, Germany) [11, 21], and BRAF mutations in exon 15 (codon 600) were detected by either polymerase chain reaction (PCR)- restriction fragment length polymorphisms or highresolution melting analysis,…”
MethodSelf-citationOoki, A., Akagi, K., Yatsuoka, T., Asayama, M., Hara, H., Takahashi, A., Kakuta, M., Nishimura, Y., & Yamaguchi, K. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23755 · Cited by 33
Self-citationAmikura, K., Akagi, K., Ogura, T., Takahashi, A., & Sakamoto, H. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24910 · Cited by 34
Self-citationMishima, S., Taniguchi, H., Akagi, K., Baba, E., Fujiwara, Y., Hirasawa, A., Ikeda, M., Maeda, O., Muro, K., Nishihara, H., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01498-8 · Cited by 33
“In Europe and the US, 15% of all colorectal cancers are dMMR [10], and in Japan, 6–7% are dMMR [11, 12].”
BackgroundSelf-citationClinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer
Bonetti, L. R., Barresi, V., Maiorana, A., Manfredini, S., Caprera, C., & Bettelli, S. R. (2018) · Disease Markers · doi:10.1155/2018/2959801 · Cited by 30
Low-Level Microsatellite Instability as a Potential Prognostic Factor in Sporadic Colorectal Cancer
Lee, D., Kim, D., Lee, H. S., Ihn, M. H., Oh, H., Min, B. S., Kim, W. R., Huh, J. W., Yun, J.-A., Lee, K. Y., et al. (2015) · Medicine · doi:10.1097/md.0000000000002260 · Cited by 27
KRAS and BRAF mutations in prostate carcinomas of Chinese patients
Shen, Y., Lu, Y., Yin, X., Zhu, G., & Jianshan, Z. (2010) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2009.12.003 · Cited by 26
Mechanisms of aneuploidy induction by RAS and RAF oncogenes.
Kamata, T., & Pritchard, C. A. (2011) · Europe PMC (PubMed Central) · Cited by 31
Emerging evidence of immunotherapy for colorectal cancer
Miyamoto, Y., Ogawa, K., Ohuchi, M., Tokunaga, R., & Baba, H. (2022) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12633 · Cited by 29
Terui-Kohbata, H., Tachikawa, T., Kakuta, M., Nishimura, Y., Yatsuoka, T., Yamaguchi, K., Yura, K., & Akagi, K. (2013) · Oncology Reports · doi:10.3892/or.2013.2781 · Cited by 22
Self-citationHigh Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer
Korphaisarn, K., Pongpaibul, A., Roothumnong, E., Pongsuktavorn, K., Thamlikitkul, L., Anekpuritanang, T., Poungvarin, N., Thongnoppakhun, W., & Pithukpakorn, M. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.8.2319 · Cited by 23
“…countries (Asaka et al., 2009; Lin et al., 2011; Ahn et al., 2014; Tong et al., 2014), Western countries (Lamy et al., 2011; Vaughn et al., 2011; Bozzao et al., 2012), and the TCGA database (Cancer Genome Atlas Network, 2012) – but not with all reports (Liou et al., 2011; Chaiyapan et al.,…”
BackgroundNakayama, Y., Iijima, T., Inokuchi, T., Kojika, E., Takao, M., Takao, A., Koizumi, K., Horiguchi, S., Hishima, T., & Yamaguchi, T. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01968-y · Cited by 20
Nakamura, F., Sato, Y., Okamoto, K., Fujino, Y., Mitsui, Y., Kagemoto, K., Kawaguchi, T., Miyamoto, H., Muguruma, N., Sonoda, T., et al. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01858-8 · Cited by 18
Matsunaga, M., Kaneta, T., Miwa, K., Ichikawa, W., Fujita, K., Nagashima, F., Furuse, J., Kage, M., Akagi, Y., & Sasaki, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4576 · Cited by 21
Universal screening to identify Lynch syndrome: two years of experience in a Northern Italian Center
Chiaravalli, A. M., Carnevali, I. W., Sahnane, N., Leoni, E., Furlan, D., Berselli, M., Sessa, F., & Tibiletti, M. G. (2019) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000543 · Cited by 16
“, 2016) and a frequency of 6–7% in Japan (Ishikubo et al., 2004; Asaka et al., 2009; Chika et al., 2017).”
BackgroundSpontaneous Regression of Mismatch Repair-Deficient Colon Cancer: A Case Series
Yokota, T., Saito, Y., Takamaru, H., Sekine, S., Nakajima, T., Yamada, M., Sakamoto, T., Taniguchi, H., Kushima, R., Tsukamoto, S., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.051 · Cited by 17
Mitani, S., Taniguchi, H., Sugiyama, K., Masuishi, T., Honda, K., Narita, Y., Kadowaki, S., Ura, T., Ando, M., Tajika, M., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918820298 · Cited by 14
BRAF mutations in sporadic colorectal carcinoma from polish patients.
Wójcik, P., Okoń, K., Osuch, C., Klimkowska, A., & Tomaszewska, R. (2010) · PubMed · Cited by 13
Nakayama, Y., Iijima, T., Wakaume, R., Takahashi, K., Matsumoto, H., Nakano, D., Miyaki, M., & Yamaguchi, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215513 · Cited by 12
Hinoi, T. (2021) · Journal of the Anus Rectum and Colon · doi:10.23922/jarc.2021-009 · Cited by 15
Costi, R., Santi, C., Bottarelli, L., Azzoni, C., Bian, A. Z. L., Riccò, M., Sarli, L., Silini, E. M., & Violi, V. (2016) · Journal of Surgical Oncology · doi:10.1002/jso.24282 · Cited by 12
Hatthakarnkul, P., Quinn, J. A., Matly, A., Ammar, A., Wyk, H. C. V., McMillan, D., & Edwards, J. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103490 · Cited by 12
BRAF Gene Mutation Analysis in Colorectal Cancer in South of Iran
Javadi, F., Geramizadeh, B., & Mirzai, M. (2014) · Annals of Colorectal Research · doi:10.17795/acr-19917 · Cited by 14
Azzoni, C., Bottarelli, L., Cecchini, S., Silini, E. M., Bordi, C., & Sarli, L. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1133-8 · Cited by 11
“1–35% [8–12]).”
Li, W., Zhi, W., Zou, S., Qiu, T., Ling, Y., Shan, L., Shi, S., & Ying, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128202 · Cited by 16
Inverse effect of mucinous component on survival in stage III colorectal cancer
Ooki, A., Akagi, K., Yatsuoka, T., Asayama, M., Hara, H., Yamamoto, G., Nishimura, Y., & Yamaguchi, K. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23742 · Cited by 10
Self-citationZhao, Y., Zheng, Z., Luo, Y., Piao, H., Zheng, G., Shi, J., Zhang, T., & Zhang, J. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0189-9 · Cited by 10
“Some authors argued there was no qualitatively discrete MSI-L group [5, 6], while others reported the biological and clinicopathological significance of MSI-L in tumors [27, 28].”
BackgroundTanakaya, K., Yamaguchi, T., Hirata, K., Yamada, M., Kumamoto, K., Akiyama, Y., Ishimaru, K., Okamoto, K., Kawasaki, Y., Komine, K., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02892-1 · Cited by 14
Nguyen, H. T., Le, T., Duong, Q., Tatipamula, V. B., & Nguyen, B. V. (2020) · Oncology Letters · doi:10.3892/ol.2020.12302 · Cited by 14
“(25,50), and marginally lower than other Asian populations (~4.5‑7%), including Japan (53,66) and China (69,73).”
InfluentialMishima, S., Naito, Y., Akagi, K., Hayashi, N., Hirasawa, A., Hishiki, T., Igarashi, A., Ikeda, M., Kadowaki, S., Kajiyama, H., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02397-9 · Cited by 9
Self-citationGenomic and immunological features of microsatellite instability in colon cancer
Luo, Y., Zhou, Y., Chen, Y., Lu, X., & Quan, Y. (2021) · Gene · doi:10.1016/j.gene.2021.145534 · Cited by 7
Fang, M., Lin, L., Chen, G., Xu, C., Wang, H., & Wu, Y. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.200601 · Cited by 6
RetractedHuo, J.-T., Tuersun, A., Yu, S.-Y., Zhang, Y., Feng, W., Xu, Z., Zhao, J., Zong, Y., & Lu, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-48768-0 · Cited by 7
Iwata, Y., Tanaka, C., Ohno, S., Suetsugu, T., Tanaka, H., Watanabe, T., Komori, S., Nagao, N., Katayama, M., & Kawai, M. (2024) · Surgery Today · doi:10.1007/s00595-024-02932-9 · Cited by 6
Lack of BRAFV600E mutation in stage I and II of colorectal cancer.
Molaei, M., Farahani, R. K., Maftouh, M., Taleghani, M. Y., Vahdatinia, M., Khatami, F., Mojarad, E. N., Aghdae, H. A., Aboutorabi, A., & Zali, M. R. (2016) · Gastroenterology and hepatology from bed to bench. · Cited by 7
Sugiyama, T., Iwaizumi, M., Kaneko, M., Tani, S., Yamade, M., Hamaya, Y., Furuta, T., Miyajima, H., Osawa, S., Baba, S., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11799 · Cited by 3
Kim, T.-W., Hwang, S. W., Kim, K. O., Cha, J. M., Joo, Y., & Cho, Y. (2022) · Oncology · doi:10.1159/000527285 · Cited by 4
Heriyanto, D. S., Yoshuantari, N., Akbariani, G., Lau, V., Hanini, H., Hidayati, Z., Arief, M. Z., Gunawan, A. N., Ridwanuloh, A. M., Kusharyoto, W., et al. (2024) · World Journal of Oncology · doi:10.14740/wjon1843 · Cited by 5
“A study by Asaka et al (2009) investigated KRAS mutations in different MSI status (MSI-H, MSI-L, and MSS) and reported that 93% G to A KRAS mutation occurred in MSI-H tumors compared to MSI-L and MSS [69].”
BackgroundA Model for Predicting DNA Mismatch Repair-deficient Colorectal Cancer
Chikatani, K., Chika, N., Suzuki, O., Sakimoto, T., Ishibashi, K., Eguchi, H., Okazaki, Y., & Ishida, H. (2020) · Anticancer Research · doi:10.21873/anticanres.14441 · Cited by 4
Low microsatellite instability revisited: a review
Grosser, B., Kohlruss, M., & Keller, G. (2026) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-026-04400-w · Cited by 2
“A commonly reported finding is a higher frequency of KRAS mutations in MSI-L tumours or in specific tumour subgroups [52, 55, 62, 63].”
InfluentialOtsuka, H., Murakami, Y., Uemura, K., Kondo, N., Nakagawa, N., Okada, K., Seo, S., & Takahashi, S. (2020) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.737 · Cited by 2
Chikatani, K., Chika, N., Suzuki, O., Sakimoto, T., Ishibashi, K., Eguchi, H., Okazaki, Y., & Ishida, H. (2020) · Surgery Today · doi:10.1007/s00595-020-01998-5 · Cited by 2
Paek, O. J., Oh, S. Y., Kim, Y. B., & Suh, K. W. (2010) · Journal of the Korean Society of Coloproctology · doi:10.3393/jksc.2010.26.2.145 · Cited by 1
Adjuvant Chemotherapy for Colon Cancer: Guidelines and Clinical Trials in Japan
Kotani, D., Kuboki, Y., & Yoshino, T. (2016) · Current Colorectal Cancer Reports · doi:10.1007/s11888-016-0336-3 · Cited by 1
Clinical Features of Lynch Syndrome
Tanakaya, K. (2020) · Springer eBooks · doi:10.1007/978-981-15-6891-6_2 · Cited by 1
Lynch Syndrome Caused by a Germ Line Mutation in MSH6
Suzuki, O., Kumamoto, K., Fukuchi, M., Chika, N., Hatano, S., Matsuzawa, T., KUMAGAI, Y., Ishibashi, K., Mochiki, E., & Ishida, H. (2015) · 日本消化器外科学会雑誌 · doi:10.5833/jjgs.2014.0181
Immune Checkpoint Inhibitors Against Colon Cancer
Muro, K. (2018) · Nihon Daicho Komonbyo Gakkai Zasshi · doi:10.3862/jcoloproctology.71.406
Ishibe, A., Watanabe, J., Ota, M., & Endo, I. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000004824
3) Immune Checkpoint Inhibitors for Gastrointestinal Tract Cancers
Muro, K. (2019) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.108.1777
Spontaneous Regression of Advanced Transverse Colon Cancer: A Case Report
Ohno, S., Iwata, Y., Mitsutome, S., Kawai, S., Neo, M., Fukuda, M., Wang, B., Suetsugu, T., Watanabe, T., Komori, S., et al. (2025) · Surgical Case Reports · doi:10.70352/scrj.cr.24-0018
Okano, F., Yoshida, N., Morinaga, Y., Iwai, N., Kobayashi, R., Inoue, K., Dohi, O., Ando, T., & Itoh, Y. (2025) · DEN Open · doi:10.1002/deo2.70216
“[4].”
Additional file 1 of Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Figshare · doi:10.6084/m9.figshare.20330034
A case of Lynch syndrome diagnosed after nine metachronous cancers detected over 35 years
Tsuji, Y., Inoue, A., Hashimoto, M., Kato, S., MORIMOTO, Y., Nishizawa, Y., Kagawa, Y., Hata, T., Hirota, M., Inoue, T., et al. (2026) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-026-02331-2
“While over 90% of LS colorectal cancers have been reported to show an MSI-high status [11], in Japan, this feature is only observed in approximately 6–7% of all colorectal cancer cases [12, 13].”
Self-citationLynch Syndrome in the Asian American Population: A Review of the Literature
Park, W., Mochizuki, A., Gima, L., & Jeter, J. (2026) · Cancers · doi:10.3390/cancers18091456
“Microsatellite instability is present in 12–16% of CRC in Western countries but only 6–7% of CRC in Japan [13–17].”
Zhang, Y.-Y., Fu, H., Yin, Y., Huang, J., Tian, J.-H., Lin, J., Bai, K., & Wang, Z. (2026) · The Oncologist · doi:10.1093/oncolo/oyag128
Metadata
- Authors
- Asaka, S.-I., Arai, Y., Nishimura, Y., Yamaguchi, K., Ishikubo, T., Yatsuoka, T., Tanaka, Y., & Akagi, K.
- Affiliations
- Saitama Cancer Center (JP)
- Corresponding author
- Akagi, K.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-09
- Volume
- 30
- Issue
- 3
- Pages
- 494-499
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2140416445
- Cited by
- 76
- References
- 52
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 8 · 2020: 7 · 2019: 7 · 2018: 7 · 2017: 3 · 2016: 8 · 2015: 5 · 2014: 5 · 2013: 1 · 2012: 2
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Carcinogenesis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- KRAS mutation, colorectal cancer progression, BRAF mutation, TP53 mutation, MGMT promoter methylation, MLH1 promoter methylation, tumor suppressor pathways, microsatellite instability-high, microsatellite stable colorectal cancer
- MeSH terms
- MutL Protein Homolog 1, Heterozygote, Humans, Mutation, Nuclear Proteins, Promoter Regions, Genetic, Proto-Oncogene Proteins, Colorectal Neoplasms, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), ras Proteins, Loss of Heterozygosity, O(6)-Methylguanine-DNA Methyltransferase, Proto-Oncogene Proteins B-raf, Adaptor Proteins, Signal Transducing, Microsatellite Instability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.